Posts in Uncategorized

Joint Scientific Consultations: Aligning Regulators and HTA Before the Trial Starts

The Joint Clinical Assessment has changed what a European launch dossier has to prove. What it has not changed is when that proof has to[…]

Biosimilar Switching: What Regulators Settled and What You Still Have to Prove

The scientific argument about biosimilar switching was settled some years ago. In a joint statement issued in September 2022, EMA and the Heads of Medicines[…]

Electronic Product Information: The ePI Roadmap and How to Prepare

For as long as EU medicines have been regulated, the summary of product characteristics and package leaflet have been Word documents that become PDFs that[…]

The First Joint Clinical Assessment: What the Early JCA Pipeline Tells Us

The EU Health Technology Assessment Regulation stopped being theoretical in 2026. The Member State Coordination Group on HTA endorsed the first Joint Clinical Assessment report[…]

Outsourced Pharmacovigilance: Auditing the Partners Who Run Your Safety System

Very few marketing authorisation holders run every part of their pharmacovigilance system in-house. Case processing, literature screening, local safety contacts and database hosting are routinely[…]

The Pharma Package: From Political Agreement to Implementation Plan

After more than two years of negotiation, the EU’s pharmaceutical legislation reform has a settled text. The Council and the European Parliament reached political agreement[…]

Post-Authorisation Safety Studies: Designing a PASS That Holds Up

A post-authorisation safety study is one of the few pharmacovigilance activities where a regulator reviews your methodology before you are allowed to begin. Get the[…]

Environmental Compliance for Medicines: The Revised ERA Guideline and the Wastewater Directive

The environment has become a regulatory obligation for pharmaceutical companies on two fronts at once. On one side sits the marketing authorisation dossier, where the[…]

Antimicrobial Resistance and the EU’s Search for Workable Incentives

Antimicrobial resistance is one of the most serious long-term threats to European health systems, yet the pipeline of new antibiotics has thinned to a trickle.[…]

Drug-Device Combination Products and Article 117 of the MDR: The Notified Body Opinion

Prefilled syringes, pens, autoinjectors and inhalers are medicines to their manufacturers and patients — but the device that delivers the dose has its own regulatory[…]